Business UpdateMay 14, 2026, 08:32 AM
Microbot Medical Q2 Revenue Exceeds Q1; Accounts Doubled
AI Summary
Microbot Medical Inc. announced that its Q2 revenue has already surpassed its Q1 revenue, driven by the Full Market Release of its LIBERTY Endovascular Robotic System. The number of accounts adopting the system has more than doubled since the Limited Market Release, with hospitals in six states now utilizing the technology. The company also highlighted successful procedures, including the world's first robotic Prostatic Artery Embolization, and expects accelerated commercial adoption due to industry tailwinds and continued market expansion.
Key Highlights
- Q2 revenue has already exceeded total Q1 revenue.
- Number of accounts using LIBERTY system more than doubled since end of Limited Market Release.
- LIBERTY system adopted by hospitals in six states: GA, FL, NY, MI, MA, NC.
- Boston, MA is the first city/state with multiple LIBERTY system accounts.
- Performed world's first robotic Prostatic Artery Embolization (PAE).
- New Midwest and Mid-Atlantic territories secured accounts since early April launch.